Obesity Research & Clinical Practice is an esteemed journal published by ELSEVIER SCI LTD, focusing on cutting-edge research and clinical practices related to obesity and its multifaceted impact on health and wellness. With an ISSN of 1871-403X and an E-ISSN of 1878-0318, this journal serves as a vital resource for researchers and practitioners in the fields of Endocrinology, Diabetes and Metabolism and Nutrition and Dietetics. Notably, it holds a Q2 ranking in Endocrinology, Diabetes and Metabolism and a prestigious Q1 ranking in Nutrition and Dietetics for 2023, reflecting its influence and quality within the scientific community. The journal features a broad scope of research topics encompassing clinical findings, epidemiological studies, and therapeutic advancements in obesity treatment, aiming to improve health outcomes globally. Submissions are encouraged from diverse disciplines, ensuring a dynamic and multidisciplinary approach to tackling obesity-related challenges. Given its convergence of years from 2007 to 2024, Obesity Research & Clinical Practice stands as a prominent platform for disseminating valuable knowledge, insights, and groundbreaking research in this pressing area of public health.

JOURNAL OF PSYCHOPHARMACOLOGY, published by SAGE Publications Ltd, is a leading peer-reviewed journal that explores the intricate dynamics of pharmacological interventions in mental health and psychiatry. With an ISSN of 0269-8811 and an E-ISSN of 1461-7285, this esteemed journal has established its reputation in the field since its inception in 1987, converging research excellence into 2024. Recognized as a Q1 journal in various categories including Medicine (miscellaneous), Pharmacology, and Psychiatry and Mental Health, it ranks impressively within the top percentile in Scopus, standing at #64 out of 567 in Psychiatry and Mental Health, and #31 out of 272 in Medical Pharmacology. The journal serves as a vital resource for researchers, professionals, and students, providing insightful articles that advance the understanding of psychopharmacological effects and innovations. Although it does not offer open access, the journal's extensive research and impactful findings make it essential reading for anyone engaged in the field. For those seeking to stay at the forefront of psychopharmacology, the JOURNAL OF PSYCHOPHARMACOLOGY is an invaluable asset.

Translational Psychiatry, an esteemed journal published by SpringerNature, is at the forefront of research in the fields of biological psychiatry, neuroscience, and mental health. With an impressive Q1 category ranking in Biological Psychiatry, Cellular and Molecular Neuroscience, and Psychiatry and Mental Health, the journal fosters high-quality scholarly work that informs clinical practices and guides future research directions. Since its inception in 2011, Translational Psychiatry has embraced the Open Access model, ensuring that groundbreaking findings are easily accessible to all, promoting collaboration and innovation within the global scientific community. With a solid ranking in Scopus—particularly at #33 out of 567 in Psychiatry and Mental Health and #6 out of 51 in Biological Psychiatry—this journal plays a critical role in advancing our understanding of mental health disorders, bridging the gap between bench science and clinical application. As it continues evolving through its converged years from 2011 to 2024, Translational Psychiatry remains an essential resource for researchers, healthcare professionals, and students dedicated to improving mental health outcomes.

PSYCHIATRIC QUARTERLY, published by Springer, stands as a pivotal resource in the field of psychiatry and mental health since its inception in 1927. With a reputable Q2 categorization in Psychiatry and Mental Health for 2023, this journal ranks impressively at #77 out of 567 in Scopus, placing it in the top 86th percentile of its category. Covering a diverse range of topics related to mental health, PSYCHIATRIC QUARTERLY aims to disseminate rigorous research findings, theoretical advancements, and clinical insights that contribute to improved mental health practices and policies. Although it does not offer open access, it provides substantial value to researchers, professionals, and students through its comprehensive analyses and scholarly articles. Located in New York, United States, the journal serves as an essential platform for advancing the understanding and treatment of psychiatric disorders, making it an invaluable addition to any academic library or research portfolio.

ACTA PSYCHIATRICA SCANDINAVICA is a leading journal in the field of Psychiatry and Mental Health, published by Wiley since its inception in 1926. With a strong commitment to advancing psychiatric research, this esteemed journal boasts an impressive impact factor and ranks within the top 7% of its category, reflecting its influence and relevance in the field. Operating without an Open Access model, the journal serves as a vital resource for professionals, researchers, and students keen on accessing high-quality, peer-reviewed studies focused on mental health issues. The scope of ACTA PSYCHIATRICA SCANDINAVICA spans a broad spectrum of psychiatric topics, providing a platform for groundbreaking research and clinical practice insights. Based in the United Kingdom and featuring contributions from experts worldwide, the journal continues to shape the future of psychiatric research through its rigorous publication standards and commitment to scholarly excellence.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, published by MARY ANN LIEBERT, INC, stands as a premier academic journal dedicated to advancing the field of pediatric psychopharmacology. With a rich history of publication spanning from 1990 to 2024, this journal presents cutting-edge research that informs clinical practices and policy decisions impacting the mental health of children and adolescents. Ranked in the Q2 category for both Pediatrics, Perinatology and Child Health and Pharmacology (medical) as of 2023, it reflects its critical contribution to these fields, along with a respectable Q3 status in Psychiatry and Mental Health. Researchers and practitioners benefit from the journal's rigorous peer-reviewed articles, which delve into the efficacy, safety, and ethical implications of pharmacological treatments tailored for young populations. Although the journal does not currently offer Open Access, it remains a vital resource for anyone engaged in child and adolescent health research and treatment strategies. Its commitment to fostering dialogue and innovation in psychopharmacology ensures its pivotal role in shaping future standards and practices in this essential area of medical science.

The Journal of the Academy of Consultation-Liaison Psychiatry, published by Elsevier Science Inc, stands as a pivotal resource in the fields of clinical psychology and psychiatry, with a commendable impact factor that reflects its significance in mental health research. Established in 2021, this journal has rapidly ascended within its domain, achieving a Q2 category ranking in both Clinical Psychology and Psychiatry and Mental Health as of 2023, placing it among the top journals in these fields. With a Scopus ranking of 64 out of 311 in clinical psychology and 163 out of 567 in psychiatry, it serves as an essential platform for researchers, professionals, and students to access high-quality articles that advance knowledge and practices in consultation-liaison psychiatry. The journal promotes open access initiatives, enhancing the reach and impact of its publications, and is committed to disseminating innovative research findings that contribute to improving patient care and understanding of mental health complexities. Whether you are engaged in academic, clinical, or applied research, the Journal of the Academy of Consultation-Liaison Psychiatry is your go-to source for evidence-based insights and groundbreaking studies.

Psychiatria i Psychologia Kliniczna - Journal of Psychiatry and Clinical Psychology is a vital platform for advancing the fields of psychiatry and clinical psychology, published by Medical Communications in Poland. With its ISSN 1644-6313, this Open Access journal has been providing unrestricted access to impactful research since 2005, ensuring that findings in mental health are both accessible and disseminated widely. Although currently ranked in the Q4 quartile across Clinical Psychology and Psychiatry and Mental Health categories, and with the Scopus ranks placing it at 262/311 in Clinical Psychology and 493/567 in Psychiatry, the journal serves as a crucial resource for researchers seeking to explore innovative methodologies and therapeutic interventions. The journal's aim is to enhance understanding and treatment of psychiatric disorders by facilitating the exchange of knowledge between academia and clinical practice. As it converges from 2006 to 2024, Psychiatria i Psychologia Kliniczna remains committed to publishing high-quality articles that contribute toward the evolving landscape of mental health research.

Journal of Psychiatric Practice, published by Lippincott Williams & Wilkins, is a premier journal dedicated to advancing the field of psychiatry and mental health. With a focus on evidence-based clinical practice, the journal has been a respected resource since its inception, providing a platform for a wide range of articles, including original research, reviews, and case reports from 1997 to the present. As of 2023, it holds a Q3 ranking in Psychiatry and Mental Health, reflecting its influential role in the academic community. The Journal is aimed at researchers, mental health professionals, and students, promoting the dissemination of essential knowledge and innovative practices. Subscribers benefit from the latest findings and discussions in the field while contributing to the ongoing advancements in psychiatric care. Although not classified as open access, the journal ensures wide accessibility to its valuable content, further solidifying its commitment to the mental health discipline.